Unknown

Dataset Information

PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.


ABSTRACT: Background PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors effectively lower LDL (low-density lipoprotein) cholesterol and have been shown to reduce cardiovascular outcomes in high-risk patients. We used real-world electronic health record data to characterize use of PCSK9 inhibitors, in addition to standard therapies, according to cardiovascular risk status. Methods and Results Data were obtained from 18 health systems with data marts within the National Patient-Centered Clinical Research Network (PCORnet) using a common data model. Participating sites identified >17.5 million adults, of whom 3.6 million met study criteria. Patients were categorized into 3 groups: (1) dyslipidemia, (2) untreated LDL ≥130 mg/dL, and (3) coronary artery disease or coronary heart disease. De

SUBMITTER: Chamberlain AM 

PROVIDER: S-EPMC6512121 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature